GlassScriptPhysician profile
Steven Habusta
NPI 1740245844
$1,319.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $208 · 2021: $476 · 2022: $400.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $867.78 | 2019-2022 | |
| Organogenesis INC. | $171.73 | 2019-2022 | |
| Kerecis Limited | $63.55 | 2019-2022 | |
| Medline Industries LP | $43.73 | 2020 | |
| Misonix INC | $33.75 | 2019-2020 | |
| Bioventus LLC | $32.61 | 2022 | |
| Integra Lifesciences Corporation | $21.79 | 2019 | |
| Depuy Synthes Sales INC. | $21.16 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.29 | 2020 | |
| Shire North American Group INC | $17.49 | 2019 | |
| Tactile Systems Technology INC | $14.27 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Habusta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.